Nanjing Hengdao Pharmaceutical Technology Co Ltd.

To evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of oxymetazoline hydrochloride eye drops in Chinese adult patients with acquired ptosis.

Primary objective: To evaluate the tolerability and safety of single/multiple use HD-NE02 sustained-release eye drops in healthy Chinese adults. Secondary objective: To evaluate the PK characteristics of single/multiple use HD-NE02 sustained-release eye drops in healthy Chinese adults.

Main purpose of study: According to the relevant provisions of bioequivalence test, Anacor Pharmaceuticals, Inc. is the licensee of crisaborole ointment (trade name: Sutanming®; specification: 2%) as the reference preparation, and the test preparation crisaborole ointment (specification: 2%) produced by Jiangsu Wanhe Pharmaceutical Co., Ltd. and licensed by Nanjing Hengdao Pharmaceutical Technology Co., Ltd. is used for fasting topical human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under fasting administration conditions. Secondary purpose of study: To observe the safety of the test preparation crisaborole ointment (specification: 2%) and the reference preparation crisaborole ointment (trade name: Sutanming®, specification: 2%) in fasting topical administration on healthy volunteers.